nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

01.03.2015 | Review Article

Shifting Paradigm in the Management of Anal Canal Carcinoma

verfasst von: Supriya Mallick, Rony Benson, P. K. Julka, G. K. Rath

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Anal canal is the lower most part of the gastrointestinal tract harbouring 4 % of all gastrointestinal cancer. Most common treatment for anal canal carcinoma includes chemoradiotherapy.

Methodology

We reviewed the recent landmark trials to find a road map in the management of anal canal carcinoma.

Results

Concurrent chemoradiotherapy appears to be the most effective treatment schedule. Induction, as well as maintenance chemotherapy, has no definite role. Moderate dose radiation 50.4–54 Gy with concurrent mitomycin C (MMC) and 5-fluorouracil (5-FU) remains the standard. Split course is detrimental. Intensity-modulated radiotherapy and targeted drugs are investigated.

Conclusion

Combined modality therapy is the standard for anal canal carcinoma.

Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1974;27:763–6.CrossRef

UKCCCR trial. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR anal cancer trial working party. UK Co-ordinating committee on cancer research. Lancet. 1996;19; 348(9034):1049–54.

Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;30;102(7):1123–8.CrossRef

Bartelink H et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15(5):2040.PubMed

Konski A, Garcia Jr M, John M, Krieg R, Pinover W, Myerson R, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92–08. Int J Radiat Oncol Biol Phys. 2008;72(1):114–8.CrossRefPubMedCentralPubMed

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Sun Myint A, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24.CrossRefPubMed

Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson III AB, et al. Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;10;30(35):4344–51.CrossRef

Peiffert D, Tournier-Rangeard L, Ge’rard J-P, Lemanski C, Franc¸ois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–8.CrossRefPubMed

Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;1; 86(1):27–33.CrossRef

10.

Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2001;1; 50(3):675–80.CrossRef

11.

John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92–08. Cancer J Sci Am. 1996;2(4):205–11.PubMed

12.

Matthews JHL, Burmeister BH, Borg M, Capp AL, Joseph D, Thompson KM, Thompson PI, Harvey JA, Spry NA. T1-2 anal carcinoma requires elective inguinal radiation treatment—the results of trans tasman radiation oncology group study TROG 99.02. Radiother Oncol 2011;98:93–98.

13.

Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–36.CrossRefPubMedCentralPubMed

14.

Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;10; 25(29):4581–6.CrossRef

15.

Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527–39.PubMed

16.

Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, Erlich F, Faroni L, Castro L, Lusis EC. Alessandra Marins, MN4; and Carlos Gil Ferreira. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 2013.

17.

Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013;24:2834–8.CrossRefPubMed

18.

Edge SB, Byrd DR, Compton CC, et al. American joint committee on cancer staging manual. 7th ed. New York: Springer; 2010. p. 165.

19.

Papagikos M, Crane CH, Skibber J, Janjan NA, Feig B, Rodriguez-Bigas MA, et al. Chemoradiation for adenocarcinoma of the anus. Int J Radiat Oncol Biol Phys. 2003;55:669.CrossRefPubMed

20.

Allal A, Kurtz JM, Pipard G, Marti MC, Miralbell R, Popowski Y, et al. Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison. Int J Radiat Oncol Biol Phys. 1993;27:59.CrossRefPubMed

21.

Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol. 2007;14:2807.CrossRefPubMed

22.

Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16:536.CrossRefPubMed

23.

Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol. 2013;24:3045.CrossRefPubMed

24.

Abbas A, Nehme E, Fakih M. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res. 2011;31:4637.PubMed

25.

Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum. 2007;50:395.CrossRefPubMed

Titel: Shifting Paradigm in the Management of Anal Canal Carcinoma
verfasst von: Supriya Mallick
Rony Benson
P. K. Julka
G. K. Rath
Publikationsdatum: 01.03.2015
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2015
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-014-9673-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Shifting Paradigm in the Management of Anal Canal Carcinoma

Abstract

Background

Methodology

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methodology

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Skeletal Metastasis in Gallbladder Cancer from a High-Volume Tertiary Care Center of North India: a Series of Rare Occurrence

Recurrent Hypoglycemic Coma as the Initial and Single Clinical Manifestation of Advanced Hepatocellular Carcinoma

Abrikossoff Cell Tumor of the Esophagus: Case Presentation of a Rare Endoscopic Entity and Review of Literature

Segmental Hypertrophy Mimicking Liver Tumor in a Patient with Primary Sclerosing Cholangitis

The Descriptive Epidemiology of Gastric Cancer in Central America and Comparison with United States Hispanic Populations

Anaplastic Adenocarcinoma of the Pancreas

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie